Doubling of SCr Median · people with diabetes and kidney disease
Angiotensin receptor blockers may leads to lower doubling of SCr Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Fatal or nonfatal stroke · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in fatal or nonfatal stroke Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in fatal or nonfatal myocardial infarction Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease
Angiotensin receptor blockers may leads to lower micro‐ to macroalbuminuria Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease
It is very uncertain whether angiotensin receptor blockers changes micro‐ to normoalbuminuria Median compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Death (all causes) · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in all‐cause death Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Cardiovascular mortality · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in cardiovascular death Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Death (any cause) · adults with early (stage 1 to 3) non‐diabetic CKD
1 finding from 1 review
Cardiovascular events · adults with early (stage 1 to 3) non‐diabetic CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants reporting an adverse event · adults with early (stage 1 to 3) non‐diabetic CKD
It is very uncertain whether angiotensin receptor blockers changes adverse events (number reporting an adverse event) compared with placebo (very low certainty).
1 finding from 1 review
Kidney failure progression: eGFR (mL/min/1.73m²) · adults with early (stage 1 to 3) non‐diabetic CKD
1 finding from 1 review
Death (all causes) · people with diabetes and kidney disease
1 finding from 1 review
Cardiovascular mortality · people with diabetes and kidney disease
1 finding from 1 review
Doubling of SCr · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatal or nonfatal stroke · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Micro‐ to macroalbuminuria5 · people with diabetes and kidney disease
1 finding from 1 review
Micro‐ to normoalbuminuria6 · people with diabetes and kidney disease
It is very uncertain whether dual therapy (angiotensin‐converting‐enzyme inhibitors plus… changes micro‐ to normoalbuminuria6 compared with placebo or no treatment (very low certainty).
1 finding from 1 review